ZA962012B - Improvements in or relating to organic compositions - Google Patents

Improvements in or relating to organic compositions

Info

Publication number
ZA962012B
ZA962012B ZA962012A ZA962012A ZA962012B ZA 962012 B ZA962012 B ZA 962012B ZA 962012 A ZA962012 A ZA 962012A ZA 962012 A ZA962012 A ZA 962012A ZA 962012 B ZA962012 B ZA 962012B
Authority
ZA
South Africa
Prior art keywords
relating
organic compositions
granules
andb
comprisinga
Prior art date
Application number
ZA962012A
Other languages
English (en)
Inventor
Peter William Dettmar
Paul Andrew Dickson
Frank Chadwick Hampson
Ian Gordon Jolliffe
William Peers
Original Assignee
Reckitt & Colmann Prod Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Reckitt & Colmann Prod Ltd filed Critical Reckitt & Colmann Prod Ltd
Publication of ZA962012B publication Critical patent/ZA962012B/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1635—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Compositions Of Macromolecular Compounds (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Dental Preparations (AREA)
ZA962012A 1995-03-13 1996-03-13 Improvements in or relating to organic compositions ZA962012B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB9505032.4A GB9505032D0 (en) 1995-03-13 1995-03-13 Improvements in or relating to organic compositions

Publications (1)

Publication Number Publication Date
ZA962012B true ZA962012B (en) 1996-09-26

Family

ID=10771122

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA962012A ZA962012B (en) 1995-03-13 1996-03-13 Improvements in or relating to organic compositions

Country Status (21)

Country Link
US (1) US6306789B1 (de)
EP (1) EP0814771B1 (de)
JP (1) JPH11501652A (de)
KR (1) KR19980702970A (de)
CN (1) CN1126533C (de)
AT (1) ATE212539T1 (de)
AU (1) AU712464B2 (de)
BR (1) BR9607234A (de)
CZ (1) CZ274497A3 (de)
DE (1) DE69618934T2 (de)
ES (1) ES2167546T3 (de)
GB (2) GB9505032D0 (de)
HK (1) HK1011291A1 (de)
HU (1) HUP9900800A3 (de)
MX (1) MX9706992A (de)
NO (1) NO974194D0 (de)
NZ (1) NZ302741A (de)
PL (1) PL184407B1 (de)
TR (1) TR199700943T1 (de)
WO (1) WO1996028141A1 (de)
ZA (1) ZA962012B (de)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AP1224A (en) * 1998-03-19 2003-11-14 Bristol Myers Squibb Co Biphasic controlled release delivery system for high solubility pharmaceuticals and method.
GB9809347D0 (en) * 1998-05-05 1998-07-01 Reckitt & Colmann Prod Ltd Compositions
IN190017B (de) * 1999-01-25 2003-05-31 Panacea Biotech Ltd
EP1347748A2 (de) 2000-12-05 2003-10-01 MacGregor, Alexander Hydrostatisches abgabesystem für die kontrollierte abgabe eines mittels
AU2002319653A1 (en) * 2001-07-20 2003-03-03 Samir Mitragotri Method for oral drug delivery
US6572889B1 (en) * 2002-03-07 2003-06-03 Noveon Ip Holdings Corp. Controlled release solid dosage carbamazepine formulations
US7198653B2 (en) 2003-07-31 2007-04-03 Delavau Llc Calcium carbonate granulation
US8497258B2 (en) 2005-11-12 2013-07-30 The Regents Of The University Of California Viscous budesonide for the treatment of inflammatory diseases of the gastrointestinal tract
US8679545B2 (en) * 2005-11-12 2014-03-25 The Regents Of The University Of California Topical corticosteroids for the treatment of inflammatory diseases of the gastrointestinal tract
US8324192B2 (en) 2005-11-12 2012-12-04 The Regents Of The University Of California Viscous budesonide for the treatment of inflammatory diseases of the gastrointestinal tract
US9138414B1 (en) 2006-09-15 2015-09-22 Delavau Llc Calcium supplement having enhanced absorption
EP3620153A1 (de) 2007-07-06 2020-03-11 Lupin Limited Pharmazeutische zusammensetzungen zur wirkstoffverabreichung im magen-darm-trakt
US20120027855A1 (en) 2007-07-06 2012-02-02 Lupin Limited Pharmaceutical compositions for gastrointestinal drug delivery
US8974825B2 (en) * 2007-07-06 2015-03-10 Lupin Limited Pharmaceutical compositions for gastrointestinal drug delivery
US20090123390A1 (en) * 2007-11-13 2009-05-14 Meritage Pharma, Inc. Compositions for the treatment of gastrointestinal inflammation
WO2009064819A2 (en) * 2007-11-13 2009-05-22 Meritage Pharma, Inc. Compositions for the treatment of gastrointestinal inflammation
US20090123551A1 (en) * 2007-11-13 2009-05-14 Meritage Pharma, Inc. Gastrointestinal delivery systems
US20100216754A1 (en) * 2007-11-13 2010-08-26 Meritage Pharma, Inc. Compositions for the treatment of inflammation of the gastrointestinal tract
US11969501B2 (en) 2008-04-21 2024-04-30 Dompé Farmaceutici S.P.A. Auris formulations for treating otic diseases and conditions
US20090264392A1 (en) * 2008-04-21 2009-10-22 Meritage Pharma, Inc. Treating eosinophilic esophagitis
EP2278999A4 (de) 2008-04-21 2015-04-22 Otonomy Inc Ohrbehandlungsformulierungen zur behandlung von ohrenerkrankungen und -leiden
US8784870B2 (en) * 2008-07-21 2014-07-22 Otonomy, Inc. Controlled release compositions for modulating free-radical induced damage and methods of use thereof
CN102105133B (zh) 2008-07-21 2015-06-17 奥德纳米有限公司 控制释放型耳结构调节和先天性免疫系统调节组合物以及治疗耳部病症的方法
PT2328553T (pt) 2008-08-20 2020-08-25 Univ California Corticosteroides para o tratamento de doenças inflamatórias do trato gastrointestinal
WO2014149617A1 (en) * 2013-03-15 2014-09-25 Cook Medical Technologies Llc Adhesive medical products and methods for treating gastrointestinal lesions
US11931227B2 (en) 2013-03-15 2024-03-19 Cook Medical Technologies Llc Bimodal treatment methods and compositions for gastrointestinal lesions with active bleeding
KR20180037994A (ko) 2015-07-28 2018-04-13 오토노미, 인코포레이티드 TrkB 또는 TrkC 아고니스트 조성물 및 귀 병태의 치료 방법
WO2018005830A1 (en) 2016-06-29 2018-01-04 Otonomy, Inc. Triglyceride otic formulations and uses thereof
WO2019067680A1 (en) 2017-09-27 2019-04-04 Cook Medical Technologies Llc CROSSLINKING SUBMUCOSAL INJECTION SYSTEM
WO2019154895A1 (en) 2018-02-08 2019-08-15 Strekin Ag Gel formulation for preventing or treating hearing loss
CN114904007B (zh) * 2022-04-24 2024-04-05 南京紫鸿生物科技有限公司 一种提高卡波姆的堆积密度的方法

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS60237054A (ja) 1984-05-10 1985-11-25 Nippon Kayaku Co Ltd アミノ酸の晶析法
GB8428952D0 (en) 1984-11-16 1984-12-27 Beecham Group Plc Formulations
US4772475A (en) * 1985-03-08 1988-09-20 Yamanouchi Pharmaceutical Co., Ltd. Controlled-release multiple units pharmaceutical formulation
US5057317A (en) 1987-03-24 1991-10-15 Chugai Seiyaku Kabushiki Kaisha Slow-release pharmaceutical agent
EP0297866A3 (de) 1987-07-01 1989-12-13 The Boots Company PLC Arzneimittel
GB9010039D0 (en) * 1990-05-03 1990-06-27 Reckitt & Colmann Prod Ltd Medicament preparation
DE4036757A1 (de) * 1990-11-17 1992-05-21 Bayer Ag Antazida-zubereitung mit verlaengerter magenverweilzeit
TW209174B (de) * 1991-04-19 1993-07-11 Takeda Pharm Industry Co Ltd
US5350584A (en) * 1992-06-26 1994-09-27 Merck & Co., Inc. Spheronization process using charged resins
EP0995447A1 (de) * 1993-09-09 2000-04-26 Takeda Chemical Industries, Ltd. Formulierung enthaltend einen Antibakteriellen und einen Antiulcus Wirkstoff

Also Published As

Publication number Publication date
KR19980702970A (ko) 1998-09-05
ES2167546T3 (es) 2002-05-16
EP0814771B1 (de) 2002-01-30
MX9706992A (es) 1997-11-29
AU4886896A (en) 1996-10-02
PL184407B1 (pl) 2002-10-31
US6306789B1 (en) 2001-10-23
HUP9900800A2 (hu) 1999-07-28
CN1126533C (zh) 2003-11-05
NO974194L (no) 1997-09-11
PL322065A1 (en) 1998-01-05
BR9607234A (pt) 1997-11-11
NO974194D0 (no) 1997-09-11
GB2298790A (en) 1996-09-18
CN1178458A (zh) 1998-04-08
DE69618934D1 (de) 2002-03-14
DE69618934T2 (de) 2002-09-12
GB2298790B (en) 1999-06-30
GB9505032D0 (en) 1995-05-03
HK1011291A1 (en) 1999-07-09
AU712464B2 (en) 1999-11-04
TR199700943T1 (xx) 1998-02-21
WO1996028141A1 (en) 1996-09-19
HUP9900800A3 (en) 2001-02-28
JPH11501652A (ja) 1999-02-09
CZ274497A3 (cs) 1998-03-18
NZ302741A (en) 1999-08-30
ATE212539T1 (de) 2002-02-15
EP0814771A1 (de) 1998-01-07
GB9604678D0 (en) 1996-05-01

Similar Documents

Publication Publication Date Title
GB2298790B (en) Improvements in or relating to organic compositions
AU4063697A (en) Methods for regulating gastrointestinal motility
CA2342340A1 (en) New sustained release oral formulations
CA2304958A1 (en) Bioadhesive compositions and methods for topical administration of active agents
DK1183014T3 (da) Smagsmaskerede orale farmaceutiske sammensætninger med kontrolleret frigivelse
WO1997038662A3 (en) Buccal polar spray or capsule
CA2131350A1 (en) Sustained release drug formulation containing a tramadol salt
ZA9711732B (en) Methods and compositions for improvement bioavailability of bioactive agents for mucosal delivery
GB0122318D0 (en) Organic compounds
IL150895A0 (en) Oral, nasal and pulmonary formulations of copolymer-1
CA2326198A1 (en) Cosolvent formulations
EP0966966A3 (de) Nefazodon enthaltende Dosierungsform
WO2000013662A3 (en) Medicated chewing gum delivery system for nicotine
PL1608349T3 (pl) Układ do ustnego dostarczania zawierający środek przeciwbakteryjny i środek przeciwzapalny
IL142284A0 (en) A pharmaceutical composition containing an agent which blocks the binding of lymphotoxin-b to its receptor
AU1244199A (en) Tablets to be crunched or sucked, comprising iron as active principle
AP1485A (en) Orally administered controlled delivery system for once daily administration of ciprofloxacin.
CA2214979A1 (en) Improvements in or relating to organic compositions
MXPA02006034A (es) Formas de dosis mucosaloral de apomorfina.
WO2003040316A3 (en) Selective elimination of cd52+ cells and uses thereof
CA2252038A1 (en) Buccal polar spray or capsule